Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 November 1996

High doses of alphacalcidol given once a week - a new method of treatment of uraemic secondary hyperparathyroidism

Ewa Pacocha, Joanna Matuszkiewicz-Rowińska, Stanisław Niemczyk, Marek Świtalski, Barbara Bogdańska-Straszyńska, Kazimierz Ostrowski

Med Sci Monit 1996; 2(6): CR784-788 :: ID: 500494


High dose pulse iv or oral 1,25 (OH)2,D3,/1(αOH)D3, therapy in uremic hyperparathyroidism has been shown to be much more effective than daily standard doses. The problem of hypercalcemia, however, still exists. Since in the last years protracted fall in serum PTH was found after a single dose of 1,25 (OH)2,D3, we decided to check whether 1(αOH)D3, administrated once weekly is effective in parathyroid hyperactivity of chronic renal failure. 17 hemodialysis patients with advanced hyperparathyroidism were given oral alphacalcidol in doses of 6 (g once a week, during the dialysis session. Dialysate calcium was 1.40 - 1.45 moll/l, and CaCO3, (up to 6 g/day) was used as the main phosphate binder; in 6 patients Al(OH)3, (up to 3 g/day) was added. The doses of 1 (αOH)D3,CaCO3, and Al(OH)3, were modified according to the calcium and phosphate levels. Serum 1 - 84 PTH decreased significantly after 2 weeks (p (0.02), and then the reduction of parathyroid activity progressed to 51&plusm;6.1&percnt; at the end of the study. The normalisation of PTH secretion was seen only in one patient and the treatment was ineffective in 4 patients; 3 of them had initial serum PTH levels (800 pg/ml. The serum 1,25 (OH)2,D3, levels increased from 8.5±1.08 pg/ml to 17.0±2.72 pg/ml (p<0.025). Serum total calcium, phosphate, alkaline phosphatase activity and hydroxyproline levels did not change significantly, nor did the doses of 1α(OH)D3,CaCO3, and Al(OH)3,. The incidence of hypercalcemia was 2.6% hese results indicate that oral pulse therapy with alphacalcidol administered once a week effectively reduces PTH secretion in hemodialysis patients with moderate hyperparathyroidism, with low risk of hypercalcemia and oversuppression of parathyroid activity.

Keywords: alphacalcidol, chronic renal failure, uremic hyperparathyroidism, hemodialysis

Add Comment 0 Comments

530 0


01 June 2023 : Editorial  

Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.941209

Med Sci Monit 2023; 29:e941209

In Press

01 Jun 2023 : Clinical Research  

Root Canal Numbers and Configurations in 1080 Permanent Canine Teeth in 270 Saudi Subjects Using Cone-Beam ...

Med Sci Monit In Press; DOI: 10.12659/MSM.940472  

01 Jun 2023 : Clinical Research  

Internal Orifice Alloy Closure: A New Procedure for Treatment of Perianal Fistulizing Crohn’s Disease

Med Sci Monit In Press; DOI: 10.12659/MSM.940873  

01 Jun 2023 : Clinical Research  

Effectiveness of Needle Aspiration versus Surgical Excision for Symptomatic Synovial Cysts of the Hip: A Si...

Med Sci Monit In Press; DOI: 10.12659/MSM.940187  

01 Jun 2023 : Clinical Research  

Influence of Insulin Resistance on Diabetes Nephropathy

Med Sci Monit In Press; DOI: 10.12659/MSM.939482  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788


30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750